Wegovy® pill prescriptions surpass 3 million, 1 filled roughly every 5 seconds, bringing GLP-1 therapy to people with obesity previously untreated, while Novo Nordisk unveils new data at ADA 2026

Three million prescriptions for Wegovy® pill since launch on January 5th serve as another milestone in one of the strongest US pharmaceutical launches by volume on record1

The majority of new Wegovy® pill prescriptions are for people new to GLP-1 therapy, bringing obesity medicine to many previously untreated1

This news comes as Novo Nordisk has a large presence at the American Diabetes Association’s 2026 Scientific Sessions, including a variety of Wegovy® analyses in adults with obesity

Novo Nordisk today announced Wegovy® (semaglutide) tablets 25 mg have surpassed three million prescriptions in just over five months, establishing Wegovy® pill as one of the strongest US pharmaceutical launches by volume on record.¹ The three million milestone corresponds to one prescription filled roughly every five seconds, reflecting continued uptake since Wegovy® pill became available in January 2026. Further underscoring its rapid adoption, Wegovy® pill reached its initial one million prescription milestone just 12 weeks after reaching US pharmacies and online providers (week of 1/5/26 to week of 3/23/26), with an additional two million prescriptions accumulated in an even shorter span of just 10 weeks (week of 3/23/26 to week of 6/1/26). The majority of new prescriptions filled for Wegovy® pill (more than 80%) are for people new to GLP-1 therapy, indicating the oral formulation is expanding the obesity treatment market, rather than replacing existing therapies.¹

“Wegovy® offers adults with obesity significant weight loss, along with diet and exercise, and is FDA-approved to lower the risk of major cardiovascular events such as death, heart attack, or stroke in adults with obesity with known heart disease – making Wegovy® pill truly distinct. With Wegovy® pill and Wegovy® HD available for weight management, patients and their healthcare providers are making choices that fit their needs, resulting in the clear adoption for both treatments,” said Jamey Millar, executive vice president, US Operations of Novo Nordisk. “Novo Nordisk remains determined to continue playing a major part in addressing the global public health challenge of obesity by deeply understanding the needs of those who live with it. That is why we are at ADA 2026 – to talk to patients, healthcare professionals, and investors to present our data but also listen and learn”

This year, more patients starting a new weight management therapy have filled prescriptions for Wegovy® than any other available obesity medication. Alongside the three million prescription milestone for Wegovy® pill, the recently launched Wegovy® HD (semaglutide) injection 7.2 mg has demonstrated strong uptake in the early days of availability.1

Expanding affordable access to medicines is a priority for Novo Nordisk, including the expansion of coverage for those with insurance in the US. Those with commercial insurance coverage can access Wegovy® for as little as $25 per month through existing savings programs.* The recently announced Medicare GLP-1 Bridge builds on these efforts to expand access and will provide eligible Medicare beneficiaries living with obesity access to Wegovy® (semaglutide) injection and tablets for a $50 monthly copay†, beginning July 1, 2026. In addition, Wegovy® is available through a range of access options, including more than 70,000 US pharmacies, NovoCare® Pharmacy, select telehealth providers, and others

This announcement coincides with Novo Nordisk presenting an array of clinical data at the American Diabetes Association® 2026 86th Scientific Sessions in New Orleans (June 5-8, 2026), including a variety of Wegovy® analyses in adults with obesity

Novo Nordisk is preparing for the first launches of the Wegovy® pill outside the United States in the second half of 2026, including the recently announced approval and launch in the United Arab Emirates

Investor relations event

Novo Nordisk will host an investor event covering ADA 2026 data and the Wegovy® pill commercial milestone on 7 June 7, 2026 at 6:30 pm CDT. The event will be accessible via live webcast on the Novo Nordisk investor website

*Pay as little as $25, subject to a maximum savings of $100/month. Eligibility and restrictions apply. Government beneficiaries excluded. Month defined as 1 box of 4 pens of Wegovy and 1 bottle of 30 tablets of Wegovy. Novo Nordisk reserves the right to modify or cancel this program at any time. See full terms at WegovyTerms.com and NovoCarePharmacyTerms.com

†Terms apply. For eligible Medicare patients prescribed Wegovy for a covered FDA-approved indication. Eligibility criteria will be determined by CMS. This information is not a guarantee of coverage. Month defined as 1 box of 4 pens of Wegovy® and 1 bottle of 30 tablets of Wegovy®